BRPI0923780A2 - Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto - Google Patents

Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto

Info

Publication number: BRPI0923780A2
Authority: BR; Brazil
Prior art keywords: compound; kilogram; composition; treating cancer; preparation process
Prior art date: 2008-12-31

Application number

BRPI0923780-1A

Other languages

English (en)

Inventor

Anantha Sudhakar

Tamilarasan Subramani

Mohamed Sheik Mohamed Mujeebur Rahuman

Ramar Subbiah

Original Assignee

Sunesis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-31

Filing date

2009-12-29

Publication date

2015-07-21

2009-12-29 Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc

2015-07-21 Publication of BRPI0923780A2 publication Critical patent/BRPI0923780A2/pt

Links

150000001875 compounds Chemical class 0.000 title 4
238000000034 method Methods 0.000 title 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
238000000354 decomposition reaction Methods 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0923780-1A 2008-12-31 2009-12-29 Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto BRPI0923780A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14185608P	2008-12-31	2008-12-31
PCT/US2009/069645 WO2010078294A1 (en)	2008-12-31	2009-12-29	Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid

Publications (1)

Publication Number	Publication Date
BRPI0923780A2 true BRPI0923780A2 (pt)	2015-07-21

Family

ID=42103392

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0923780-1A BRPI0923780A2 (pt)	2008-12-31	2009-12-29	Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto

Country Status (19)

Country	Link
US (4)	US8497282B2 (pt)
EP (2)	EP2382214B1 (pt)
JP (3)	JP6129471B2 (pt)
KR (2)	KR20170090535A (pt)
CN (1)	CN102341393B (pt)
AR (2)	AR074962A1 (pt)
AU (3)	AU2009335159B2 (pt)
BR (1)	BRPI0923780A2 (pt)
CA (1)	CA2748066C (pt)
ES (1)	ES2646093T3 (pt)
IL (1)	IL213708A (pt)
MX (1)	MX2011006974A (pt)
NZ (1)	NZ593763A (pt)
RU (2)	RU2015106671A (pt)
SG (2)	SG10201504789RA (pt)
TW (1)	TWI469980B (pt)
UA (1)	UA108194C2 (pt)
WO (1)	WO2010078294A1 (pt)
ZA (2)	ZA201104610B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2559652C (en)	2004-03-15	2017-02-14	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 in treating cancer
US20100048609A1 (en) *	2006-08-01	2010-02-25	Jacobs Jeffrey W	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2214662B1 (en)	2007-10-22	2016-07-13	Sunesis Pharmaceuticals, Inc.	(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en)	2007-12-10	2010-11-17	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
UA110465C2 (en)	2009-09-04	2016-01-12	Sunesis Pharmaceutecals Inc	Stable sns-595 composition
TW201120037A (en) *	2009-10-26	2011-06-16	Sunesis Pharmaceuticals Inc	Compounds and methods for treatment of cancer
CN112638363B (zh) *	2018-08-31	2025-01-24	太阳医药工业有限公司	卡铂的肠胃外剂型
WO2026003045A1 (en)	2024-06-26	2026-01-02	Janssen Pharmaceutica Nv	Synthesis of a malt1 inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6233176A (ja)	1985-08-05	1987-02-13	Toyama Chem Co Ltd	１，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2995704B2 (ja) *	1989-02-17	1999-12-27	東京化成工業株式会社	光学活性な１ｈ−３−アミノピロリジン化合物の製造法
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JP3312459B2 (ja) *	1993-12-28	2002-08-05	東レ株式会社	光学活性アミンの単離方法
DK0787726T3 (da)	1994-06-14	2002-02-11	Dainippon Pharmaceutical Co	Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
JP4323574B2 (ja)	1995-12-13	2009-09-02	大日本住友製薬株式会社	抗腫瘍剤
JPH10173986A (ja)	1996-12-16	1998-06-26	Sony Corp	移動体撮影装置
JP4294121B2 (ja)	1998-06-05	2009-07-08	大日本住友製薬株式会社	ピリドンカルボン酸誘導体の製造方法およびその中間体
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
CA2559652C (en) *	2004-03-15	2017-02-14	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 in treating cancer
US8580814B2 (en)	2006-04-03	2013-11-12	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2007258280B2 (en)	2006-06-12	2013-05-02	Sunesis Pharmaceuticals, Inc.	Compounds and compositions for treatment of cancer
US20100048609A1 (en)	2006-08-01	2010-02-25	Jacobs Jeffrey W	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US7790274B2 (en)	2006-08-02	2010-09-07	High Impact Technology, Llc	Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials
DK2049109T3 (en)	2006-08-02	2016-01-11	Sunesis Pharmaceuticals Inc	Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2214662B1 (en)	2007-10-22	2016-07-13	Sunesis Pharmaceuticals, Inc.	(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en)	2007-12-10	2010-11-17	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2010099526A1 (en)	2009-02-27	2010-09-02	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en)	2009-09-04	2016-01-12	Sunesis Pharmaceutecals Inc	Stable sns-595 composition
TW201120037A (en)	2009-10-26	2011-06-16	Sunesis Pharmaceuticals Inc	Compounds and methods for treatment of cancer

2009
- 2009-12-29 KR KR1020177021219A patent/KR20170090535A/ko not_active Ceased
- 2009-12-29 JP JP2011544574A patent/JP6129471B2/ja active Active
- 2009-12-29 KR KR1020117017736A patent/KR101765956B1/ko not_active Expired - Fee Related
- 2009-12-29 RU RU2015106671/04A patent/RU2015106671A/ru not_active Application Discontinuation
- 2009-12-29 SG SG10201504789RA patent/SG10201504789RA/en unknown
- 2009-12-29 MX MX2011006974A patent/MX2011006974A/es active IP Right Grant
- 2009-12-29 SG SG2011048444A patent/SG172457A1/en unknown
- 2009-12-29 AU AU2009335159A patent/AU2009335159B2/en not_active Ceased
- 2009-12-29 NZ NZ593763A patent/NZ593763A/xx not_active IP Right Cessation
- 2009-12-29 EP EP09796587.5A patent/EP2382214B1/en not_active Not-in-force
- 2009-12-29 CN CN200980157710.2A patent/CN102341393B/zh not_active Expired - Fee Related
- 2009-12-29 BR BRPI0923780-1A patent/BRPI0923780A2/pt not_active IP Right Cessation
- 2009-12-29 ES ES09796587.5T patent/ES2646093T3/es active Active
- 2009-12-29 RU RU2011132119/04A patent/RU2548031C2/ru not_active IP Right Cessation
- 2009-12-29 EP EP17179724.4A patent/EP3284745A1/en not_active Withdrawn
- 2009-12-29 CA CA2748066A patent/CA2748066C/en not_active Expired - Fee Related
- 2009-12-29 WO PCT/US2009/069645 patent/WO2010078294A1/en not_active Ceased
- 2009-12-29 UA UAA201109496A patent/UA108194C2/uk unknown
- 2009-12-30 AR ARP090105186A patent/AR074962A1/es not_active Application Discontinuation
- 2009-12-30 US US12/650,390 patent/US8497282B2/en not_active Expired - Fee Related
- 2009-12-31 TW TW98146462A patent/TWI469980B/zh not_active IP Right Cessation
2011
- 2011-06-21 IL IL213708A patent/IL213708A/en not_active IP Right Cessation
- 2011-06-22 ZA ZA2011/04610A patent/ZA201104610B/en unknown
2012
- 2012-10-05 ZA ZA2012/07483A patent/ZA201207483B/en unknown
2013
- 2013-07-11 US US13/940,157 patent/US8802719B2/en not_active Expired - Fee Related
2014
- 2014-07-11 US US14/329,765 patent/US20150157614A1/en not_active Abandoned
2015
- 2015-06-09 JP JP2015116753A patent/JP6174627B2/ja not_active Expired - Fee Related
- 2015-07-24 AU AU2015205924A patent/AU2015205924A1/en not_active Abandoned
2016
- 2016-03-08 US US15/064,498 patent/US9839630B2/en not_active Expired - Fee Related
2017
- 2017-05-23 AR ARP170101388A patent/AR108558A2/es unknown
- 2017-06-08 AU AU2017203865A patent/AU2017203865A1/en not_active Abandoned
- 2017-07-06 JP JP2017132768A patent/JP2017214400A/ja active Pending

Also Published As

Publication number	Publication date
SG172457A1 (en)	2011-08-29
NZ593763A (en)	2013-11-29
AR108558A2 (es)	2018-08-29
KR20170090535A (ko)	2017-08-07
TWI469980B (zh)	2015-01-21
IL213708A (en)	2016-02-29
AU2009335159B2 (en)	2015-07-23
JP2012514041A (ja)	2012-06-21
EP2382214A1 (en)	2011-11-02
IL213708A0 (en)	2011-07-31
ZA201104610B (en)	2014-03-26
JP2017214400A (ja)	2017-12-07
JP2015180677A (ja)	2015-10-15
AU2017203865A1 (en)	2017-06-22
US20140171660A1 (en)	2014-06-19
AU2009335159A1 (en)	2011-07-14
EP3284745A1 (en)	2018-02-21
US8802719B2 (en)	2014-08-12
UA108194C2 (uk)	2015-04-10
AR074962A1 (es)	2011-02-23
MX2011006974A (es)	2011-11-18
US8497282B2 (en)	2013-07-30
CA2748066A1 (en)	2010-07-08
CN102341393A (zh)	2012-02-01
RU2011132119A (ru)	2013-02-10
US20100203162A1 (en)	2010-08-12
TW201036970A (en)	2010-10-16
SG10201504789RA (en)	2015-07-30
WO2010078294A8 (en)	2011-11-10
JP6174627B2 (ja)	2017-08-02
EP2382214B1 (en)	2017-07-19
KR20110116145A (ko)	2011-10-25
US9839630B2 (en)	2017-12-12
WO2010078294A1 (en)	2010-07-08
US20150157614A1 (en)	2015-06-11
ES2646093T3 (es)	2017-12-12
CA2748066C (en)	2017-06-27
JP6129471B2 (ja)	2017-05-17
RU2015106671A (ru)	2015-06-27
RU2548031C2 (ru)	2015-04-10
US20170035741A1 (en)	2017-02-09
CN102341393B (zh)	2014-09-17
KR101765956B1 (ko)	2017-08-07
AU2015205924A1 (en)	2015-08-20
ZA201207483B (en)	2016-06-29

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-10-22	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2020-02-11	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2546 DE 22-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0923780A2 (pt)	2015-07-21	Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto
BRPI0919488A2 (pt)	2015-12-01	composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BRPI0909006A2 (pt)	2015-09-15	composto, composição, método para tratar o câncer em um mamífero, método para inibir angiogênese em um mamífero e inibir uma via de sinalização hedgehog em uma célula, processo para preparar um composto
BRPI1005940A2 (pt)	2019-09-24	processo para preparar compostos de 2-nitrobifenila de fórmula i, compostos de 2-aminobifenila de fórmula vi, n-acil-2-aminobifenilas da fórmula geral (vii), composto de fórmula i, composto de fórmula ii, composto de fórmula iii e composto de fórmula x.1 ou x.2
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0812521A2 (pt)	2015-06-23	Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0921687A2 (pt)	2015-08-18	Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BR112012002251A2 (pt)	2016-06-14	processo para fabricação de composto da fórmula (1), composto da fórmula (a), composto da fórmula (b), método analítico, composto da fórmula iv, compostos, processos, métodos e usos inovadores
BRPI1009022A2 (pt)	2016-03-08	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI1010937A2 (pt)	2019-09-24	composto, uso de um composto, e, método para tratar câncer
BRPI0915101A2 (pt)	2017-03-21	composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BRPI0917589A2 (pt)	2015-11-17	composto, composição farmacêutica, uso de um composto, método para tratar doenças, processo, combinação farmacêutica, e, reação de metiloxirano-2-carboxilato (ix) com um álcool roh
BRPI0811275A2 (pt)	2014-12-23	Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0817721A2 (pt)	2015-03-31	Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
BRPI0911898A2 (pt)	2015-10-13	processo para preparar compostos, e, composto.
BR112015003698A2 (pt)	2017-07-04	compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método para o tratamento de câncer
BRPI0814012A2 (pt)	2015-02-03	Processo para produção de (met)acrilatos
BRPI0915856A2 (pt)	2015-11-03	processo para preparar micropartículas, uso de um auxiliar de processamento, micropartículas, e, composição
EP2144504A4 (en)	2012-10-03	METHOD FOR COMBATING BRAIN CANCER
BRPI0911709A2 (pt)	2017-06-20	composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
BRPI0912388A2 (pt)	2017-09-26	composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
BRPI0817445A2 (pt)	2015-10-27	composto, composição farmacêutica, método de tratamento, e, processo para preparar um composto
BRPI1011363A2 (pt)	2016-03-15	"composto, composição farmacêutica, uso de composto, método para tratar câncer de próstata, e, processo para a preparação de um composto"